FocaL Mass Drug Administration for Vivax Malaria Elimination

FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic and asymptomatic screening for malaria infections, provision of insecticide-treated bednets, and environmental transmission monitoring, will be compared to clusters of villages randomized to receive anti-malarial drugs.

NCT Number	NCT05690841
Lead Sponsor	University of California, San Francisco Collaborators: Universidad Peruana Cayetano Heredia, PATH, Stanford University, Oxford University Clinical Research Unit Indonesia, Menzies School of Health Research, National Institute of Allergy and Infectious Diseases (NIAID), GlaxoSmithKline, Medicines for Malaria Venture
Conditions	Plasmodium Vivax Malaria, Malaria
Enrollment	7,530 participants
Start Date	2024-10-14
Primary Completion	2027-05-01 (estimated)
Study Completion	2027-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-09